Results 121 to 130 of about 1,115 (163)

Cyclic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia (ITP): Diagnostic and Therapeutic Lessons. [PDF]

Cureus
Seeburun S, Lee E, Salameh S, Eltoukhy H.   +3 more
europepmc   +1 more source

Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre. [PDF]

J Clin Med
Alonso-Carballo A, López M, Jiménez M, Pérez S, García-Mañó L, Sánchez JM, Bento L, Novo A, Pérez A, Ballester C, Gutiérrez A, Puget G, Galmés B, Palomero A, Sampol A, Canaro M.   +15 more
europepmc   +1 more source

2026 ASH ITP guidelines: rethinking therapy. [PDF]

Blood Adv
Mathew C, Zumberg M.
europepmc   +1 more source

Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study. [PDF]

Hematol Rep
Baysal M, Köseoğlu FD, Sadri S, Ataş Ü, Demirci U, Çiftçiler R, Akpınar S, Ümit EG.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Avatrombopag for the Treatment of Immune Thrombocytopenia

Expert Review of Clinical Immunology, 2019
Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator.
Joanna Zdziarska, Wojciech Jurczak, Monika Długosz-Danecka   +2 more
exaly   +3 more sources